International Flavors & Fragrances Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
We view IFF as a widely held public company in the midst of one of the more ambitious portfolio transformations we track, having roughly doubled in size through its 2021 merger with DuPont's Nutrition and Biosciences business before embarking on a multi-year simplification program that has generated roughly $10.0 billion in gross divestiture proceeds across 13 transactions. In our assessment, the 2026 announced sale of a 90 percent stake in the Food Ingredients division, IFF's largest segment by revenue at $3.28 billion, to CVC Capital Partners for $4.30 billion represents the culmination of this restructuring, since it removes the company's lowest-margin major business line while retaining a 10 percent residual stake that preserves some upside participation. We think Chief Executive Officer Erik Fyrwald's continued execution of this strategy, following the completed 2025 sale of Pharma Solutions to Roquette for $2.85 billion, demonstrates sustained board level conviction that a more concentrated portfolio centered on Taste, Scent, and Health and Biosciences will command a premium valuation relative to the diversified structure inherited from the DuPont merger. We calculate that these three continuing segments carry meaningfully higher EBITDA margins, in the range of 19 to 26 percent, than the divested Food Ingredients and Pharma Solutions businesses, supporting management's stated rationale for the restructuring. We believe the absence of any confirmed activist campaign targeting IFF specifically, despite the considerable scale of recent portfolio change, suggests the dispersed institutional shareholder base has broadly endorsed management's divestiture strategy rather than needing external pressure to drive it. In our view, this combination of major inorganic scaling through the DuPont merger followed by disciplined portfolio pruning represents a genuinely different capital allocation approach than either pure organic growth or pure acquisition-led expansion. For IFF shareholders, we think the central ownership question going forward is whether the leaner, higher-margin portfolio remaining after the Food Ingredients sale closes will deliver the valuation re-rating that has evidently motivated this multi-year restructuring effort.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Dodge & Cox's roughly 13.7 percent stake stands as IFF's largest disclosed institutional position, narrowly ahead of Vanguard Group near 11.9 percent and BlackRock near 7.1 percent, with State Street, First Eagle Investment Management, and Invesco rounding out a genuinely dispersed shareholder base of roughly 1,140 institutional owners. We think Dodge & Cox's substantial value-oriented position, one of the largest single holdings in the stock, likely reflects that firm's characteristic long-horizon investment approach, potentially well suited to a company mid-way through a multi-year portfolio restructuring whose full valuation benefits may take several more years to materialize. In our assessment, the absence of any confirmed activist involvement at IFF, despite the considerable scale of recent divestiture activity, suggests the company's largest holders have broadly supported management's portfolio simplification strategy rather than pushing for a different approach through public pressure campaigns. We calculate that continued institutional ownership through both the completed Pharma Solutions sale and the pending Food Ingredients transaction indicates shareholders have accepted near term reported revenue declines, evident in fiscal 2025's 5 percent reported sales decrease, as the acceptable cost of building a more focused, higher-margin business. We believe the roughly $10.0 billion in gross divestiture proceeds generated across 13 transactions provides IFF's board considerable flexibility for future capital allocation, whether toward debt reduction, share repurchases, or further strategic investment in the retained Taste, Scent, and Health and Biosciences segments. For IFF shareholders, we think this dispersed, value-investor-weighted ownership base has provided management the patience needed to execute a multi-year restructuring rather than facing pressure for a faster but potentially less value-maximizing resolution.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Frutarom | Subsidiary | Natural flavor and fine ingredients maker acquired in 2018, integrated into the Taste division |
| Taste | Division | Flavor compounds and ingredients business serving food and beverage manufacturers |
| Scent | Division | Fragrance compounds business serving fine fragrance, personal care, and household product makers |
| Health and Biosciences | Division | Enzymes, probiotics, and specialty ingredients business serving food, health, and industrial customers |
| Food Ingredients | Division | Texturant and food ingredient business, with a 90 percent stake agreed to be sold to CVC Capital Partners in 2026 |
Portfolio Analysis
IFF's brand portfolio has narrowed meaningfully through its multi-year restructuring, concentrating now on the Taste, Scent, and Health and Biosciences divisions following the 2025 sale of Pharma Solutions and the pending 2026 sale of a 90 percent stake in Food Ingredients. We think the 2018 acquisition of Frutarom Industries for $7.10 billion, integrated into the Taste division, remains one of the company's more successful brand additions, having brought natural flavor and fine ingredients capabilities that strengthened IFF's position in a category increasingly favored by health-conscious consumers. In our assessment, the 2021 merger with DuPont's Nutrition and Biosciences business fundamentally reshaped the company's brand architecture, adding the Health and Biosciences division's enzymes, probiotics, and specialty ingredients capabilities that had no meaningful precedent in IFF's pre-merger portfolio. We believe the pending sale of the Food Ingredients division, IFF's largest segment by revenue, represents a genuinely significant brand portfolio simplification, since it removes an entire product category from the company's offering rather than merely divesting underperforming assets within a retained segment. For IFF shareholders, we think the practical brand question going forward is whether the remaining Taste, Scent, and Health and Biosciences segments can sustain the kind of premium positioning with customers that management's higher-margin strategic rationale for the restructuring depends on.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Givaudan | N/A | $8.20B FY2025 | Swiss flavors and fragrances leader and the largest company in the industry by market capitalization |
| Symrise AG | N/A | $5.20B FY2025 | German flavors and fragrances company competing directly across Taste and Scent product categories |
| DSM-Firmenich | N/A | $7.60B FY2025 | Combined nutrition and fragrance group formed by the 2023 merger of Firmenich and DSM, closely mirroring IFF's post-DuPont merger scale and business mix |
| International Flavors & Fragrances Inc. ★ | N/A | $10.89B FY2025 | New York based flavors, fragrances, and specialty ingredients company serving food, beverage, personal care, and health customers worldwide |
Competitive Analysis
Givaudan, the Swiss flavors and fragrances leader with roughly $8.20 billion in fiscal 2025 revenue, represents IFF's most direct and largest competitor, commanding the industry's largest market capitalization and setting the primary competitive benchmark against which IFF's post-restructuring performance will likely be measured. We think DSM-Firmenich, formed through the 2023 merger of Firmenich and DSM and generating roughly $7.60 billion in fiscal 2025 revenue, poses a particularly relevant competitive comparison, since that combination closely mirrors IFF's own post-DuPont merger scale and diversified business mix spanning fragrance and nutrition-adjacent categories. In our assessment, Symrise AG, the German flavors and fragrances company generating roughly $5.20 billion in fiscal 2025 revenue, competes with IFF across overlapping Taste and Scent product categories while maintaining a somewhat more concentrated focus than either IFF or DSM-Firmenich's broader diversified portfolios. We calculate that IFF's ongoing portfolio simplification, narrowing toward higher-margin Taste, Scent, and Health and Biosciences segments while divesting Food Ingredients and Pharma Solutions, represents a direct competitive response to the margin profiles Givaudan and Symrise AG have historically achieved through more focused business mixes. We believe the pending closure of the Food Ingredients sale to CVC Capital Partners will likely bring IFF's overall margin structure into closer alignment with these focused competitors, potentially narrowing a valuation gap that has persisted since the more diversified DuPont merger integration. For IFF shareholders, we think the central competitive question is whether the leaner post-restructuring portfolio can match Givaudan's and Symrise AG's historical margin performance closely enough to close IFF's valuation discount within the flavors and fragrances industry.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Frutarom Industries | $7.10B | 2018 | Acquired a natural flavor and fine ingredients maker, substantially expanding the Taste division |
| DuPont Nutrition and Biosciences | $45.40B | 2021 | Merged with DuPont's nutrition and biosciences business in a Reverse Morris Trust transaction, roughly doubling the company's size |
Acquisitions Analysis
IFF's acquisition history centers on two transformational transactions, the 2018 purchase of Frutarom Industries for $7.10 billion and the considerably larger 2021 merger with DuPont's Nutrition and Biosciences business valued at roughly $45.40 billion in enterprise value, structured as a Reverse Morris Trust transaction that roughly doubled the company's overall scale. We think the scale gap between these two deals illustrates how dramatically the DuPont merger reshaped IFF, moving the company from a mid-cap flavors and fragrances specialist into a considerably larger diversified ingredients business spanning taste, scent, and biosciences. In our assessment, the subsequent divestiture program, generating roughly $10.0 billion in gross proceeds across 13 transactions including the 2022 Savory Solutions sale, the 2025 Pharma Solutions sale, and the pending 2026 Food Ingredients transaction, functions as a deliberate unwinding of portfolio elements that no longer fit the company's strategic focus following the DuPont integration. We calculate that this pattern, major inorganic scaling followed by disciplined divestiture, suggests IFF's board and management concluded that certain acquired or legacy businesses, however individually viable, diluted the overall portfolio's margin profile relative to a more concentrated alternative. We believe the retention of a 10 percent stake in the divested Food Ingredients business, rather than a complete exit, reflects a pragmatic hedge that preserves some financial participation in that division's performance while still achieving the primary goal of deconsolidating its lower margins from IFF's reported results. For IFF shareholders, we think the key forward looking question is whether the company's acquisition strategy, once the current divestiture program concludes, will shift back toward selective bolt-on additions within the retained Taste, Scent, and Health and Biosciences segments.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
IFF's structural history centers on two defining events on opposite ends of the scale spectrum: the transformational 2021 merger with DuPont's Nutrition and Biosciences business, valued at roughly $45.40 billion and structured as a Reverse Morris Trust transaction that roughly doubled the company's size, and the subsequent multi-year divestiture program that has since generated roughly $10.0 billion in gross proceeds across 13 separate transactions. We think the Reverse Morris Trust structure used for the DuPont merger, a tax-efficient mechanism for combining a spun-off business with an existing public company, reflects sophisticated deal structuring that allowed IFF to roughly double in scale without the tax consequences a straightforward cash acquisition of that size would have triggered. In our assessment, the subsequent divestitures, including the 2022 Savory Solutions sale, the 2025 Pharma Solutions sale to Roquette, and the 2026 announced Food Ingredients sale to CVC Capital Partners, collectively represent one of the more extensive post-merger portfolio rationalization efforts among large-cap materials companies we track. We believe this sequence, dramatic inorganic scaling followed by equally dramatic selective divestiture, demonstrates that management viewed the DuPont merger as bringing genuinely valuable core capabilities in Taste, Scent, and Health and Biosciences alongside less strategically fitting businesses that warranted subsequent exit. For IFF shareholders, we think this history of major structural change, both additive and subtractive, within a roughly five-year span suggests the company's current portfolio configuration should be evaluated as a deliberately engineered endpoint rather than an accident of historical accumulation.
Ownership History
Ownership History Analysis
IFF traces its origins to 1958, formed through a merger building on roots dating to 1889's Polak and Schwarz, growing over more than six decades into a leading flavors and fragrances company before the transformational 2021 merger with DuPont's Nutrition and Biosciences business roughly doubled its scale. We think the company's history since that merger, encompassing a sustained divestiture program generating roughly $10.0 billion in gross proceeds across 13 transactions, represents one of the more deliberate post-merger portfolio rationalization efforts among the materials companies we track. The 2024 to 2026 period brought this restructuring to its culmination under Chief Executive Officer Erik Fyrwald, with the 2025 completion of the Pharma Solutions sale to Roquette for $2.85 billion and the 2026 announced sale of a 90 percent Food Ingredients stake to CVC Capital Partners for $4.30 billion. We believe fiscal 2025's reported revenue decline to $10.89 billion, alongside positive comparable currency-neutral growth of 2 percent, illustrates the near term financial trade-off management has accepted in pursuit of a leaner, higher-margin long term portfolio. For IFF shareholders, the arc from a 1958 founding through more than six decades of flavors and fragrances leadership, a transformational 2021 merger, and a 2021-2026 restructuring period illustrates how a company can use both major acquisition and major divestiture as complementary tools within a single coherent long term strategy.
Ownership Explained
International Flavors & Fragrances is a widely held public company with no founder or controlling shareholder, trading on the New York Stock Exchange under ticker IFF since roughly doubling in size through its 2021 merger with DuPont's Nutrition and Biosciences business. Dodge & Cox holds the largest disclosed institutional stake at roughly 13.7 percent, followed by Vanguard Group near 11.9 percent and BlackRock near 7.1 percent, among roughly 1,140 institutional owners. The company reported fiscal 2025 net sales of $10.89 billion, down 5 percent on a reported basis though up 2 percent on a comparable currency-neutral basis, reflecting a multi-year portfolio simplification program that has generated roughly $10.0 billion in gross divestiture proceeds, including the 2025 sale of Pharma Solutions to Roquette and the 2026 announced sale of a 90 percent stake in the Food Ingredients division to CVC Capital Partners. Chief Executive Officer Erik Fyrwald, in the role since 2024, continues executing this portfolio-focus strategy under Chairman Roger W. Ferguson Jr., concentrating the company's remaining operations on the higher-margin Taste, Scent, and Health and Biosciences segments.
Because IFF has no controlling shareholder, its multi-year portfolio restructuring, including the sale of a 90 percent stake in its largest segment by revenue, runs through an independent board accountable to a broad institutional shareholder base rather than to a founder or strategic parent. For customers across food, beverage, and personal care industries, this structure means the company's narrowing focus toward Taste, Scent, and Health and Biosciences reflects board level strategic conviction about where IFF can compete most effectively, not any single investor's short term preference. We think the dispersed ownership also means continued portfolio simplification, should management pursue further divestitures beyond the pending Food Ingredients transaction, would similarly run through ordinary board governance rather than a controlling holder's direction.